LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

Yuanshuai Su; Xinyu Gu; Qiuxian Zheng; Lingxiao Zhu; Juan Lu; Lanjuan Li

doi:10.3389/fonc.2022.847745

LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

Front Oncol. 2022 Feb 21:12:847745. doi: 10.3389/fonc.2022.847745. eCollection 2022.

Authors

Yuanshuai Su¹, Xinyu Gu¹, Qiuxian Zheng¹, Lingxiao Zhu¹, Juan Lu¹, Lanjuan Li¹

Affiliation

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Abstract

As novel members of the noncoding RNA family, long noncoding RNAs (lncRNAs) have been widely reported to function as powerful regulators in gene expression processes, including chromosome remodeling, transcription interference and posttranscriptional modification. With the rapid development of metagenomic sequencing, numerous studies have indicated that the dysregulation of lncRNAs is closely associated with diverse human diseases, especially cancers. Prostate Gene Expression Marker 1 (PCGEM1), a recently identified lncRNA, has been reported to play a crucial role in the initiation and progression of multiple tumors by interacting with pivotal regulators of tumor-related signaling pathways. In this review, we will retrospectively review the recent studies of the expression of lncRNA PCGEM1 in human cancers and comprehensively describe the underlying regulatory mechanism by which PCGEM1 functions in tumors. More importantly, based on the relationship between PCGEM1 and cancers, the potential application of PCGEM1 in clinical diagnosis, prognosis and therapeutic treatment will also be highlighted.

Keywords: PCGEM1; biomarker; cancer; lncRNA; mechanism.

Publication types

Review